share_log

Ad Hoc: Arkadius Pichota and Lukas Gilgen Appointed to Management Board of MorphoSys AG Replacing the Current CEO and CFO

Ad Hoc: Arkadius Pichota and Lukas Gilgen Appointed to Management Board of MorphoSys AG Replacing the Current CEO and CFO

臨時委員會:Arkadius Pichota和Lukas Gilgen被任命爲MorphoSys AG管理委員會成員,取代現任CEO和CFO。
MorphoSys ·  06/06 12:00

MorphoSys AG / Key word(s): Personnel
Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO
06-Jun-2024 / 22:19 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014

Planegg/Munich, Germany, June 6, 2024

Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO

Following the closing of the takeover offer by Novartis BidCo AG to the shareholders of MorphoSys AG (the "Company") (FSE: MOR; NASDAQ: MOR) and the resignation of Marc Cluzel, George Golumbeski, Krisja Vermeylen, Michael Brosnan and Andrew Cheng from the Company's supervisory board, the Munich Local Court appointed Heinrich Moisa, Romain Lege and Silke Mainka as new members. The newly composed Supervisory Board held its first meeting today and resolved to appoint Arkadius Pichota and Lukas Gilgen to the Company's management board. Arkadius Pichota, who until now served as President, General Manager and Chairman of the Board of the Novartis subsidiary Navigate BioPharma Services, Inc., has been appointed as the new CEO and Lukas Gilgen, who until now served as Transaction Lead Enterprise Projects with Novartis International AG, has been appointed as the new CFO. Jean-Paul Kress's and Lucinda Crabtree's membership of the Company's Management Board has ended today.

***

END OF AD HOC ANNOUNCEMENT


End of Inside Information

Information and Explanation of the Issuer to this announcement:

About MorphoSys

At MorphoSys, we are driven by our mission: More life for people with cancer. As a global biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter at X and LinkedIn.

MorphoSys Forward-Looking Statements

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs, effects of the acquisition of MorphoSys by Novartis AG on relationships with employees, other business partners or governmental entities, that Novartis AG may not realize the potential benefits of the acquisition of MorphoSys, potential operational difficulties with integrating MorphoSys with Novartis AG and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission, including the Solicitation/Recommendation Statement on Schedule 14D-9 regarding the acquisition of MorphoSys by Novartis AG. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

For more information, please contact:

MorphoSys AG

Dr. Julia Neugebauer

Vice President, Global Head of Investor Relations

Tel: +49 (0)89 / 899 27 179

julia.neugebauer@morphosys.com


06-Jun-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


MorphoSys AG / 關鍵字:人事調動
市場消息:Arkadius Pichota和Lukas Gilgen被提名爲MorphoSys AG的管理層,接替現任公司CEO和CFO
2024年6月6日22:19(CET / CEST)披露根據EU) No 596/2014法規第17條根據《MAR》的內部信息,由EQS News EQS Group AG服務傳遞的內部信息。
EQS News - EQS Group AG的服務披露根據EU) No 596/2014法規第17條根據《MAR》的內部信息。
發行人對此公告的內容單獨負責。


根據EU) No. 596/2014條例第17段第1款披露的內部信息的發佈

德國慕尼黑普蘭克(Planegg/Munich),2024年6月6日

市場消息:Arkadius Pichota和Lukas Gilgen被提名爲MorphoSys AG的管理層,接替現任公司CEO和CFO

在Novartis BidCo AG對MorphoSys AG(該"公司")(FSE:MOR;NASDAQ:MOR)的股東的收購要約結束和Marc Cluzel、George Golumbeski、Krisja Vermeylen、 Michael Brosnan和Andrew Cheng從公司監事會辭職後 ,慕尼黑地方法院任命了Heinrich Moisa,Romain Lege和Silke Mainka作爲新成員。 新組建的監事會今天舉行了第一次會議,並決定任命Arkadius Pichota和Lukas Gilgen作爲公司的管理層。 前Navigate BioPharma Services,Inc.總裁,總經理和董事會主席的Arkadius Pichota已被任命爲新任CEO,前Novartis International AG企業項目的交易領導的Lukas Gilgen 被任命爲新的CFO。 Jean-Paul Kress和Lucinda Crabtree的公司董事會成員資格今天結束了。

***

AD HOC公告結束


內部信息結束

發佈者就此公告的信息和說明:

關於MorphoSys

MorphoSys的任務是推動醫療,爲癌症患者創造更多可能。我們是一家全球生物製藥公司,致力於開發和交付創新藥物,旨在重新定義癌症治療方式。 MorphoSys總部位於德國普蘭克(Planegg)全球業務則在美國馬薩諸塞州波士頓開展。 欲了解更多信息,請訪問我們的網站www.morphosys.comTwitter at XMorphoSys前瞻性陳述www.morphosys.com和我們一起Twitter at X和頁面。LinkedIn.

MorphoSys前瞻性陳述

本通信包含涉及MorphoSys公司集團的某些前瞻性陳述。此類前瞻性聲明所包含的信息反映了MorphoSys截止本公告日期的判斷,並涉及已知及未知的風險和不確定性,而這些風險和不確定性可能導致MorphoSys的實際結果,財務狀況和流動性,業績或業界結果與以往或未來結果、財務狀況和流動性、業績或業績與前瞻性聲明中表達或暗示的結果,以及業界結果有實質性不同。此外,即使MorphoSys的結果、業績、財務狀況和流動性,以及其所屬產業的發展與此類前瞻性聲明一致,也可能無法預示將來期間的結果或發展趨勢。可能導致差異的因素包括MorphoSys的預期可能是不正確的,與競爭有關的發展、臨床試驗和產品開發活動及監管批准要求的內在不確定性,MorphoSys依賴與第三方的合作關係,評估其開發計劃的商業價值,Novartis AG對購併MorphoSys的員工、其他 商業夥伴或政府實體的考慮,可能導致Novartis AG無法實現購併MorphoSys的潛在好處,整合MorphoSys與Novartis AG可能存在的重大操作困難以及包括MorphoSys的風險因素中的風險因素在內 的其他風險,包括關於MorphoSys的20-F年度報告和在美國證券交易委員會的其他文件中包括有關MorphoSys與Novartis AG之間購併MorphoSys的建議/建議陳述表14D-9的風險因素。 鑑於這些不確定性,建議讀者不要過分依賴此類前瞻性陳述。本此前瞻性聲明僅截至本文件發佈之日有效。MorphoSys明確否認對其主張進行更新的任何義務,關於對此類聲明的期望或任何基於此類聲明的聲明在發生改變或任何未發生的事件,條件或情況可能影響實際結果與前瞻性聲明所設期望的實現的,除非根據法律或法規明確要求。

更多信息,請聯繫:

morphosys AG

聚利a Neugebauer博士

投資者關係全球負責人副總裁

電話:+49 (0)89 / 899 27 179

julia.neugebauer@morphosys.com


2024年6月6日 中歐時間/中歐夏令時 EQS分發服務包括監管公告、財經/公司新聞和新聞稿。
存檔,請訪問 www.eqs-news.com


Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: investors@morphosys.com
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 1920107
語言: 英語
公司: morphosys AG
Semmelweisstr. 7
82152 Planegg
德國
電話: 電話:+49 (0)89 899 27-0
傳真: 傳真:+49 (0)89 899 27-222
電子郵件: investors@morphosys.com
閱讀我們的年報 www.morphosys.com
ISIN代碼 : DE0006632003
WKN: 663200
指數: MDAX、TecDAX
上市: 法蘭克福(主板)上市、柏林、杜塞爾多夫、漢堡、漢諾威、慕尼黑、斯圖加特、Tradegate Exchange非官方上市、納斯達克
EQS新聞 ID: 1920107
End of Announcement EQS News Service
公告結束 EQS新聞服務

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論